NovoCure Limited Ordinary Shares (NVCR)

NVCR receives FDA approval for pancreatic cancer treatment, but broader market trends are causing downward price pressure despite positive trial data.

About NovoCure Limited Ordinary Shares

NovoCure Limited Ordinary Shares (NVCR) is a healthcare company focused on TTFields therapy for cancer treatment.
NovoCure Limited Ordinary Shares uses the ticker $NVCR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

• NovoCure Limited Ordinary Shares (NVCR) social dominance hit [------] which is 256% higher than it's daily average.
• NovoCure Limited Ordinary Shares (NVCR) trading volume is up 183.48% from the previous week.
• NovoCure Limited Ordinary Shares (NVCR) social dominance is up 1013.64% from the previous week.
• NovoCure Limited Ordinary Shares (NVCR) creators is up 1720% from the previous week.
• NovoCure Limited Ordinary Shares (NVCR) engagements is up 788.38% from the previous week.
• NovoCure Limited Ordinary Shares (NVCR) mentions is up 1362.5% from the previous week.
• NovoCure Limited Ordinary Shares (NVCR) posts created is up 6128.57% from the previous week.
• NovoCure Limited Ordinary Shares Creators hit a 52-Week high of [---] for the day
• NovoCure Limited Ordinary Shares Creators hit an all time of [---] for the day
• NovoCure Limited Ordinary Shares Engagements hit a 52-Week high of [-------] for the day
• NovoCure Limited Ordinary Shares Mentions hit a 52-Week high of [---] for the day

Price: $11

Price 24-Hour Time-Series Raw Data
Despite positive news like FDA approval for pancreatic cancer treatment, NVCR's price is experiencing downward pressure, likely due to broader market trends that are currently outweighing the positive social and corporate developments.

24-Hour: -0.45% 7-Day: 8.52% 30-Day: -19.72%

1-Year High: $22.10 on 2025-02-21
1-Year Low: $10 on 2026-02-09

AltRank: [---]

AltRank 24-Hour Time-Series Raw Data
NovoCure Limited Ordinary Shares (NVCR) is currently AltRank #703 based on combined combined social and market metrics Daily Average: [-----]
[--] Week: [---] [----]
[--] Month: [---] +476
[--] Months: [---] [----]
[--] Year: [---] [----]
1-Year High: [-----] on 2026-01-29
1-Year Low: [--] on 2025-11-01

Galaxy Score: [-----]

Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +1
[--] Months: [--] +1
[--] Year: [--] [---]
1-Year High: [--] on 2025-06-10
1-Year Low: [--] on 2025-10-30

Engagements: [-----] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [-------] +788%
[--] Month: [-------] +516%
[--] Months: [-------] +16%
[--] Year: [---------] -58%
1-Year High: [-------] on 2026-02-12
1-Year Low: [--] on 2025-12-21

Engagements by network (24h): X: [-----] News: [--] TikTok: [--] Reddit: [--] YouTube: [--]

Mentions: [---] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] +1,363%
[--] Month: [---] +432%
[--] Months: [-----] +2.20%
[--] Year: [-----] -4.20%
1-Year High: [---] on 2026-02-12
1-Year Low: [--] on 2025-12-21

Mentions by network (24h): X: [---] News: [--] TikTok: [--] Reddit: [--] YouTube: [--]

Creators: [---] (24h)

Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning NovoCure Limited Ordinary Shares (NVCR) in the last [--] hours which is down 34% from [---] in the previous [--] hours Daily Average: [--]
[--] Week: [---] +1,720%
[--] Month: [---] +484%
[--] Months: [---] -18%
[--] Year: [-----] +36%
1-Year High: [---] on 2026-02-12
1-Year Low: [--] on 2025-12-21

The most influential creators that mention NovoCure Limited Ordinary Shares in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	[--]	[------]	[--]	[-----]
@ATP_Analytics	[--]	[-----]	[--]	[---]
@TheOptionsBull2	[--]	[---]	[--]	[---]
@MAlkhteeb	[--]	[------]	[--]	[---]
@goldchart2	[--]	[---]	[--]	[---]
@QuantEmperor	[--]	[-----]	[--]	[---]
@NightOwlBiotech	[--]	[-----]	[--]	[---]
@LayanAhmed5637	[--]	[--]	[--]	[--]
@RosaJim94865433	[--]	[---]	[--]	[--]
@Pro_Trader0000	[--]	[--]	[--]	[--]

View More

Sentiment: 78%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 78%
Daily Average: 71%
[--] Week: 100% no change
[--] Month: 74% +41%
[--] Months: 74% +12%
[--] Year: 74% -12%
1-Year High: 100% on 2025-02-26
1-Year Low: 8% on 2026-01-11

Most Supportive Themes:

• FDA Approval for Pancreatic Cancer Treatment: (50%) NovoCure's Optune Pax device has received FDA approval for treating locally advanced pancreatic cancer, marking a significant advancement in treatment options.
• Positive Clinical Trial Data: (30%) The PANOVA-3 trial demonstrated improved overall survival and extended time to pain progression for patients using Optune Pax, highlighting the therapy's efficacy.

Most Critical Themes:

• Market Trends Impacting Price: (70%) Broader market trends are currently exerting downward pressure on NVCR's stock price, overshadowing positive company news and developments.

Social Dominance: 0.014%

Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.014%
Daily Average: 0.00644%
[--] Week: 0.025% +0.022%
[--] Month: 0.024% +0.021%
[--] Months: 0.024% +0.017%
[--] Year: 0.024% +0.017%
1-Year High: 0.048% on 2026-02-12
1-Year Low: 0.0003% on 2025-12-21

Market Dominance: 0.00139%

Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00139%
Daily Average: 0%
1-Year High: 0.00879% on 2025-03-31
1-Year Low: 0.00129% on 2026-02-09

Market Cap: $1,225,082,872

Market Cap 24-Hour Time-Series Raw Data
Current Value: $1,225,082,872
Daily Average: $1,655,475,209
[--] Week: $1,231,801,791 +9.30%
[--] Month: $1,231,801,791 -19%
[--] Months: $1,231,801,791 -6.50%
[--] Year: $1,231,801,791 -49%
1-Year High: $2,428,031,827 on 2025-02-21
1-Year Low: $1,123,179,269 on 2026-02-09

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing